Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

ClinicalTrials.gov ID: NCT05119855

Public ClinicalTrials.gov record NCT05119855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.

Study identification

NCT ID
NCT05119855
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
165 participants

Conditions and interventions

Eligibility (public fields only)

Age range
9 Years to 11 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 27, 2022
Primary completion
Dec 11, 2023
Completion
Dec 11, 2023
Last update posted
Feb 4, 2026

2022 – 2023

United States locations

U.S. sites
38
U.S. states
17
U.S. cities
36
Facility City State ZIP Site status
Cognitive Clinical Trials, LLC ( Site 0054) Phoenix Arizona 85044
Eclipse Clinical Research ( Site 0095) Tucson Arizona 85745
Children's Clinic of Jonesboro, PA ( Site 0044) Jonesboro Arkansas 72401
Preferred Research Partners Inc. ( Site 0092) Little Rock Arkansas 72211
Coast Clinical Research, LLC ( Site 0027) Bellflower California 90706
Ark Clinical Research ( Site 0098) Long Beach California 90815
Valley Clinical Trials Inc. ( Site 0004) Northridge California 91325
Medical Center for Clinical Research ( Site 0051) San Diego California 92120
Ark Clinical Research ( Site 0108) Tustin California 92780
Emerson Clinical Research Institute ( Site 0021) Washington D.C. District of Columbia 20011
Accel Research Sites-DeLand Clinical Research Unit ( Site 0066) DeLand Florida 32720
Advanced Research for Health Improvement, LLC ( Site 0012) Immokalee Florida 34142
Acevedo Clinical Research Associates ( Site 0001) Miami Florida 33142
Alpha Science Research ( Site 0067) Miami Florida 33186
Advanced Research For Health Improvement LLC ( Site 0075) Naples Florida 34102
Comprehensive Clinical Research ( Site 0038) West Palm Beach Florida 33409
Atlanta Center for Medical Research ( Site 0055) Atlanta Georgia 30331
Mount Vernon Clinical Research ( Site 0053) Sandy Springs Georgia 30328
Clinical Research Prime ( Site 0088) Idaho Falls Idaho 83404
CBH Health ( Site 0019) Gaithersburg Maryland 20877
SKY Integrative Medical Center/SKYCRNG ( Site 0084) Ridgeland Mississippi 39157
Midwest Children's Health Research Institute ( Site 0003) Lincoln Nebraska 68505
Certified Research Associates ( Site 0090) Cortland New York 13045
Corning Center for Clinical Research ( Site 0091) Horseheads New York 14845
Carolina Institute for Clinical Research, LLC ( Site 0042) Fayetteville North Carolina 28303
M3 Wake Research, Inc. ( Site 0014) Raleigh North Carolina 27612
Dayton Clinical Research ( Site 0028) Dayton Ohio 45409
Thomas Jefferson University - Family and Community Medicine ( Site 0006) Philadelphia Pennsylvania 19107
WR-ClinSearch ( Site 0049) Chattanooga Tennessee 37421
DermResearch, Inc. ( Site 0056) Austin Texas 78759
South Texas Clinical Research ( Site 0024) Corpus Christi Texas 78404
South Texas Pediatric Research Group ( Site 0094) Del Rio Texas 78840
West Houston Clinical Research Services ( Site 0078) Houston Texas 77055
Next Level Urgent Care, LLC ( Site 0099) Houston Texas 77057
Milton Haber, M.D. ( Site 0069) Laredo Texas 78041
University of Texas Medical Branch ( Site 0026) League City Texas 77573
University of Utah ( Site 0076) Salt Lake City Utah 84132
Velocity Clinical Research, Salt Lake City ( Site 0025) West Jordan Utah 84088

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05119855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 4, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05119855 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →